Vivo Diagnóstico has been acquired by NEXXUS-IBERIA SGEIC, S.A.
NEXXUS-IBERIA SGEIC, S.A. a private equity firm in Spain, has completed its acquisition of a majority stake in Vivo Diagnóstico. With this financial backing from NEXXUS-IBERIA, Vivo will focus on inorganic growth as well as investing in service quality, innovation and efficiency.
Vivo Diagnóstico is a large provider of diagnostic imaging services. It owns a network of clinics located in Andalusia, Madrid and Aragon and offers services throughout Spain, providing diagnostic imaging services in mobile units, outsourced diagnostic services for hospitals and teleradiology services.
For over 25 years, the private equity firm NEXXUS-IBERIA has partnered with entrepreneurs and management teams to consolidate and accelerate the growth of their businesses.
Oaklins’ team in Spain advised Vivo Diagnóstico on all aspects of the transaction, from the design to the execution, negotiation and closing of the deal.
Sprechen Sie mit dem Deal Team
Transaktionen
Die Lindenhofgruppe veräussert ihre Mehrheitsbeteiligung an der LabPoint an Affidea Switzerland
Die LabPoint Medizinische Laboratorien AG wurde von Affidea Switzerland AG übernommen. Mit Affidea hat die Lindenhofgruppe AG einen starken strategischen Partner für die Weiterentwicklung der LabPoint gewonnen. Die Lindenhofgruppe bleibt bedeutende Aktionärin und Grosskundin des Unternehmens. Damit schafft sie die Grundlage für eine nachhaltige Weiterentwicklung von LabPoint unter einer neuen Ankeraktionärin. LabPoint soll ihre Position in der Labordiagnostik weiter stärken und gezielt ausbauen.
Mehr erfahrenEuroHospital Varna has been acquired by Intermedica Group
EuroHospital Varna has been acquired by Intermedica Group, allowing the business to continue to grow and deliver high-quality healthcare services to its patients. Through the transaction, Intermedica Group expands its healthcare presence and intends to build a new model of integrated personalized care focused on preventive, holistic and digital medicine.
Mehr erfahrenOlyos Group has acquired a controlling stake in NewScience
Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.
Mehr erfahren